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The mammalian target of rapamycin (mTOR), a Ser/Thr protein kinase that mediates intracellular signalling related to cell growth,
proliferation, and differentiation, has received considerable interest as a possible target for cancer treatment. We evaluated the
correlation of mTOR expression with clinicopathological features, outcomes, and the expression of Akt, an upstream regulator of
mTOR, in gastric cancer. Tumour samples were obtained from 109 patients with gastric adenocarcinomas who underwent a radical
gastrectomy. The expressions of phosphorylated mTOR (p-mTOR) and phosphorylated Akt (p-Akt) in the cytoplasm and in the
nucleus were analysed by immunohistochemical staining. Cytoplasmic p-mTOR expression positively correlated with the depth of
tumour invasion (T1 vs T2–4, P¼0.003), involved lymph nodes (P¼0.010), and tumour stage (I vs II–IV, P¼0.002). In contrast,
nuclear p-mTOR expression negatively correlated with these variables (Po0.001,¼0.035, and o0.001). Cytoplasmic p-mTOR
expression was associated with significantly poorer relapse-free survival (RFS, P¼0.037) and overall survival (OS, P¼0.024), whereas
nuclear p-mTOR expression was associated with better RFS and OS (P¼0.029, 0.059). Neither cytoplasmic nor nuclear p-Akt
expression was associated with any clinicopathological factor or with survival. Localisation of p-mTOR may play an important role in
tumour progression and outcomes in patients with gastric cancer.
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Gastric cancer is one of the most common malignancies
worldwide and ranks as the second leading cause of cancer-related
death (Kamangar et al, 2006). Outcomes remain poor in patients
with unresectable or metastatic gastric cancer. Their median
survival has improved, but is still only about 1 year, even with
intensive chemotherapy (Van Cutsem et al, 2006; Cunningham
et al, 2008; Koizumi et al, 2008). Anticancer drugs aimed at
molecular regulators, including epidermal growth factor receptor
(EGFR or HER1), its homologue c-erb-2 (HER2), have been
developed and shown to be effective in the breast, lung, and colon
cancers (Slamon et al, 2001; Thatcher et al, 2005; Gatzemeier et al,
2007; Sobrero et al, 2008). These drugs have been evaluated in
advanced gastric cancer, but two EGFR tyrosine kinase inhibitors
were found to be ineffective (Dragovich et al, 2006; Rojo et al,
2006).
The mammalian target of rapamycin (mTOR) has received
considerable attention as a possible target for cancer treatment
(Huang and Houghton, 2002). mTOR is a Ser/Thr protein kinase
that mediates nutrient-dependent intracellular signalling related to
cell growth, proliferation, and differentiation. It also functions by
integrating extracellular signals such as growth factors. mTOR
promotes translation initiation by phosphorylating two targets,
ribosomal p70S6 kinase (S6K1) and eukaryotic translation
initiation factor 4E binding protein 1 (4E-BP1) (Schmelzle and
Hall, 2000; Petroulakis et al, 2006). Rapamycin is a macrolide
antibiotic and an immunosuppressive agent that inhibits mTOR.
Its antiproliferative effect is mediated through the formation of an
active complex. Rapamycin also suppresses angiogenesis by
decreasing the production of vascular endothelial growth factor
(Guba et al, 2002). mTOR inhibitor has shown promising efficacy
in a phase III clinical trial in patients with metastatic renal cell
cancer (Motzer et al, 2008). The anticancer effect of RAD001, a
rapamycin analogue, has also been shown in advanced gastric
cancer (Muro et al, 2008). However, few studies have assessed
correlations of mTOR expression in human cancers with either
clinocopathological features or outcomes (Zhou et al, 2004; Rajan
et al, 2008).
Akt, also known as protein kinase B, is an upstream regulator of
mTOR. Three isoforms of Akt have been identified, Akt1, Akt2,
and Akt3. Increased expression of Akt isoform was reported in
various cancers. Akt is a key intermediate of signalling pathways
that regulate cellular processes involved in cell growth, proli-
feration, survival, and neo-vascularization. Akt has also been
shown to play an important role in the chemotherapeutic
resistance of tumour cells. The Akt signal transduction path-
way is thus considered a promising target for chemotherapy
(Altomare and Testa, 2005). However, elevated Akt activity was not
associated with tumour progression or poor outcomes in several
studies (Tsao et al, 2003; Shah et al, 2005; Chadha et al, 2006).
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sPhosphorylated Akt (p-Akt) expression was reported in preneo-
plastic lesions such as bronchial dysplasia, suggesting that activated
Akt has an early role in tumour progression (Tsao et al, 2003;
Balsara et al, 2004). Activated Akt has also been frequently observed
in gastric cancer (Bellacosa et al, 2005), although two studies
showed no correlation of activated Akt with tumour progression or
poor survival (Nam et al, 2003; Oki et al,2 0 0 5 ) .
Both Akt and mTOR are activated by phosphorylation. This
study examined correlations of phosphorylated mTOR (p-mTOR)
expression with clinicopathological features, outcomes, and p-Akt
expression in gastric cancer. The expressions of p-mTOR and
p-Akt were evaluated immunohistochemically.
PATIENTS AND METHODS
Patients
The study group comprised 109 patients with primary gastric
adenocarcinomas who underwent curative gastrectomy (R0) from
January 1999 to December 2002 at the Department of Esophago-
gastric Surgery, Tokyo Medical and Dental University. Each
tumour was classified according to the tumour-node-metastasis
classification recommended by the International Union against
Cancer (UICC). All patients were evaluated for recurrent disease by
examination of tumour markers or by diagnostic imaging,
including computed tomography, ultrasonography, magnetic
resonance imaging, and endoscopy, every 3–6 months. No patient
received neoadjuvant therapy, although five patients with stage IV
disease received postoperative adjuvant chemotherapy with S-1.
The median follow-up time was 1953 days (range: 50–3197).
Recurrent disease was diagnosed in 29 patients (27%) and was the
cause of death in 28 of these patients.
Immunostaining of p-mTOR and p-Akt
Immunohistochemical staining was carried out by the strepta-
vidin–biotin method using a Histofine SAB-PO kit (Nichirei Co.,
Tokyo, Japan). Polyclonal rabbit anti-human antibodies against
p-mTOR (Ser
2448) and p-Akt (Ser
473) were purchased from Cell
Signaling Technology, Inc. (Beverly, MA, USA). All available
haematoxylin and eosin stained slides of the surgical specimens
were reviewed. For each case, representative paraffin blocks were
selected for immunohistochemical studies. Three-micrometer-
thick sections were cut from formalin-fixed, paraffin-embedded
tissue blocks. After deparaffinisation and rehydration, antigen
retrieval treatment was carried out at 1211C (autoclave) for 5min
in 10nmoll
 1 sodium citrate buffer (pH9.0), followed by treatment
with 3% hydrogen peroxide for 15min to quench endogenous
peroxidase activity. Nonspecific binding was blocked by treating
the slides with 5% EzBlock (including 5% normal goat serum and
0.1% Tween 20) for 60min at room temperature. The slides were
incubated with primary antibodies including p-mTOR (dilution
1:50) and p-Akt (1:50) overnight at 41C. Immunodetection was
performed by the conventional streptavidin–biotin method with a
Nichirei SAB-PO kit. The slides were counterstained with 1%
Mayer’s haematoxylin.
The p-mTOR and p-Akt levels were classified into three groups
based on both staining intensity and positive frequency according
to the scoring method described by (Zhou et al, 2004). Tumours in
which o10% of cells were weakly stained were scored as 0,
tumours in which 410% of cells were weakly stained or o20% of
cells were strongly stained were scored as 1, and tumours in which
420% of cells were strongly stained were scored as 2. A score of ‘1’
or ‘2’ was defined as ‘positive’ expression, and a score of ‘0’ was
defined as ‘negative’ expression. We counted stained cells under a
microscope to derive the scores. Cytoplasmic staining and nuclear
staining were evaluated separately.
Statistical analysis
The w
2 test was used to test possible associations between the
expression of p-mTOR or p-Akt and clinicopathological factors. It
was also used to assess correlations between p-mTOR and p-Akt
expressions. The Mann–Whitney U-test was used to analyse the
relation between each type of expression and age. Kaplan–Meier
curves were plotted to assess the effects of p-mTOR and p-Akt
expressions on relapse-free survival (RFS) and overall survival
(OS). Survival curves were compared using the log-rank test.
P-values of 0.05 or less were considered to indicate statistical
significance. Multivariate proportional Cox models were used to
assess the prognostic significance of p-mTOR and p-Akt expres-
sions and of several clinicopathological factors. Statistical analysis
was carried out with the use of SPSS Base, version 11.0 and SPSS
Advanced Models, version 11.0 (SPSS Inc, Chicago, IL, USA)
software.
RESULTS
Cytoplasmic expression of p-mTOR was found in 69 (63%) of all
tumours, and nuclear expression was found in 33 (30%).
Cytoplasmic expression of p-Akt was observed in 94 (86%)
tumours, and nuclear expression was observed in 45 (43%). No
p-mTOR or p-Akt staining was detected in normal gastric mucosa
(Figure 1).
There was no correlation between p-mTOR and p-Akt expres-
sion, but many tumours with cytoplasmic p-mTOR expression
showed cytoplasmic p-Akt expression. Nearly all the tumours with
nuclear p-mTOR or p-Akt expression showed cytoplasmic expres-
sion of the same molecule (Table 1).
The cytoplasmic expression of p-mTOR positively correlated
with the depth of tumour invasion (T1 vs T2–4; P¼0.003), lymph
node involvement (P¼0.010), and UICC stage (I vs II–IV;
P¼0.002). Nuclear p-mTOR expression negatively correlated with
the depth of tumour invasion, lymph node involvement, and the
UICC stage (Po0.001,¼0.035 and o0.001, respectively). Neither
cytoplasmic nor nuclear p-Akt expression was related to any
clinicopathological factor. The rates of cytoplasmic p-mTOR and
p-Akt expressions were slightly, but not significantly, higher
among younger patients (Tables 2 and 3).
Patients with cytoplasmic p-mTOR expression had significantly
shorter RFS and OS than those without cytoplasmic p-mTOR
expression (P¼0.037, 0.024, respectively). In contrast, nuclear
p-mTOR expression was associated with significantly longer RFS
(P¼0.029), as well as with slightly, but not significantly, longer OS
(P¼0.053). We next classified patients into the following four
subgroups according to the p-mTOR expression of their tumours
and analysed survival: patients with positive expressions of both
cytoplasmic and nuclear p-mTOR (group A), positive expression
of only cytoplasmic p-mTOR (B), positive expression of only
nuclear p-mTOR (C), and negative expressions of both cyto-
plasmic and nuclear p-mTOR (D). Survival was significantly
poorer in group B than in the other three groups (vs group A, C,
and D; P¼0.031, 0.049, and 0.036, respectively). There were no
other significant differences in this analysis. In contrast, neither
cytoplasmic nor nuclear expression of p-Akt was associated with
either RFS (P¼0.74, 0.40, respectively) or OS (P¼0.77, 0.65,
respectively) (Figure 2).
The prognostic relevance of p-mTOR and p-Akt expression was
assessed using a multivariate proportional-hazards model adjusted
for established clinical prognostic factors (i.e., depth of tumour
invasion, lymph node involvement, histological type, sex, and age)
(Table 4). The depth of tumour invasion and lymph node
involvement were independent prognostic factors (hazard ratio
(HR)¼6.62, 95% confidence interval (CI) 1.32–33.4, P¼0.022;
HR¼3.08, 95% CI 1.04–9.21, P¼0.043, respectively), but
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(HR¼1.42, 95% CI 0.51–3.97, P¼0.51).
DISCUSSION
Our study showed that p-mTOR expression was significantly
related to tumour progression and outcomes in patients with
gastric cancer. Interestingly, the cytoplasmic expression of
p-mTOR positively correlated with factors related to tumour
progression and poor outcomes in gastric cancer, whereas the
nuclear expression of p-mTOR negatively correlated with such
factors. This finding suggests that changes in the localisation of
p-mTOR may be involved in tumour progression. Other investi-
gators reported that m-TOR is mainly localised in the cytoplasm
(Janus et al, 2005; Bachmann et al, 2006), although a small fraction
of mTOR is found at a steady state in the nucleus in both normal
and malignant cells (Zhang et al, 2002). mTOR is part of two
distinct complexes: mTORC1 containing raptor and a mammalian
orthologue of yeast Lst8p (mLST8; also known as GbL), and
mTORC2 containing rictor, mLST8, and sin1 (also known as
mitogen-activated protein-kinase-associated protein 1) (Sarbassov
et al, 2005; Petroulakis et al, 2006; Rosner and Hengstschla ¨ger,
2008). mTORC1 was predominantly found in the cytoplasm of
fibroblast cells (Rosner and Hengstschla ¨ger, 2008), although its
distribution was not clear in cancer cells. mTORC1 pathway
promotes cell growth and proliferation by activating mRNA
translation and ribosome biogenesis and by inhibiting autophagy
through activation of S6K1 and inhibition of 4E-BP1. S6K1 drives
translation of 50TOP (terminal oligopyrimidine tract) mRNAs, and
4E-BP1 inhibits the mRNA cap-binding protein elF4E (Schmelzle
and Hall, 2000). 4E-BP1 and S6K1 were detected exclusively in the
cytoplasm of cancer cells (Zhang et al, 2002). We suggest that
increased cytoplasmic mTORC1 complex may activate signalling to
Table 1 Correlations among the cytoplasmic and nuclear expressions of p-mTOR and p-Akt
p-mTOR (nucleus) p-Akt (cytoplasmic) p-Akt (nucleus)
Negative Positive P-value Negative Positive P-value Negative Positive P-value
p-mTOR (cytoplasmic)
Negative 34 6 0.015 9 31 0.084 27 13 0.16
Positive 42 27 6 63 37 32
p-mTOR (nucleus)
Negative 10 66 0.77 47 29 0.31
Positive 5 28 17 16
p-Akt (cytoplasmic)
Negative 15 0 o0.001
Positive 49 45
Abbreviations: p-Akt¼phosphorylated Akt; p-mTOR¼phosphorylated mTOR.
AB C
DEF
Figure 1 No expression of p-mTOR (A) or p-Akt (D) was detected in normal gastric mucosa. Representative gastric carcinomas showing
immunostaining for p-mTOR predominantly in the cytoplasm (B) and predominantly in the nucleus (C); immunostaining for p-Akt predominantly in the
cytoplasm (E) and predominantly in the nucleus (F), magnification;  400.
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sion, although 4E-BP1 and S6K1 were not investigated in this
study. In addition, mTOR shuttles between the nucleus and the
cytoplasm (Zhang et al, 2002; Bachmann et al, 2006). The nuclear
import of mTOR has an important role in activating its
cytoplasmic signalling (Bachmann et al, 2006). However, the
mechanism of nuclear transportation of mTOR and the function of
nuclear mTOR remain unclear. Only substrates activated by
nuclear p-mTOR may not be adequate to promote tumour growth
because nuclear p-mTOR was found more frequently in early-stage
disease. On the other hand, mTORC2 is required for Akt
phosphorylation on Ser473 to achieve full activation (Sarbassov
et al, 2005). Activated Akt was not related to either tumour
progression or outcomes in this study, therefore, mTORC2 also
Table 2 Correlations between p-mTOR expression and clinicopathological factors
All
Cytoplasmic p-mTOR Nuclear p-mTOR
n (%) Negative Positive P-value Negative Positive P-value
Sex
Male 77 (71) 26 51 0.33 54 23 40.99
Female 32 (29) 14 18 22 10
Median age (range) 65 (35–85) 62 (35–79) 66 (43–85) 0.079 65 (35–85) 64 (51–81) 0.77
Depth of invasion
T1 45 (41) 24 21 0.003 23 22 o0.001
T2/3/4 41 (38)/20 (18)/4 (4) 16 48 53 11
LN metastasis
Positive (N1/2/3) 33 (30)/17 (16)/3 (3) 13 40 0.010 42 11 0.035
Negative (N0) 56 (51) 27 29 34 22
Stage
I 59 (54) 29 29 0.002 31 27 o0.001
II/III/IV 26 (24)/16 (15)/8 (7) 11 40 45 6
Recurrence
Positive 29 (27) 6 23 0.062 25 4 0.033
Negative 80 (73) 34 46 51 29
Histopathology
Intestinal 40 (37) 13 27 0.49 25 15 0.21
Diffuse 69 (63) 27 42 51 18
Abbreviations: LN metastasis¼lymph node metastasis; p-mTOR¼phosphorylated mTOR.
Table 3 Correlations between p-Akt expression and clinicopathological factors
All
Cytoplasmic p-Akt Nuclear p-Akt
n (%) Negative Positive P-value Negative Positive P-value
Sex
Male 77 (71) 9 68 0.50 45 32 0.93
Female 32 (29) 6 26 19 13
Median age (range) 65 (35–85) 58 (35–72) 65 (43–85) 0.060 64 (35–82) 66 (43–85) 0.81
Depth of invasion
T1 45 (41) 7 38 0.86 26 19 0.87
T2/3/4 41 (38)/20 (18)/4(4) 8 56 38 26
LN metastasis
Positive (N1/2/3) 33 (30)/17(16)/3(3) 6 47 0.66 30 23 0.66
Negative (N0) 56 (51) 9 47 34 22
Stage
I 59 (54) 10 48 0.28 37 21 0.25
II/III/IV 26 (24)/16 (15)/8 (7) 5 46 27 24
Recurrence
Positive 29 (27) 4 25 40.99 15 14 0.37
Negative 80 (73) 11 69 49 31
Histopathology
Intestinal 40 (37) 4 36 0.57 24 16 0.84
Diffuse 69 (63) 11 58 40 29
Abbreviations: LN metastasis¼lymph node metastasis; p-Akt¼phosphorylated Akt.
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provided evidence that cytoplasmic raptor had a higher affinity for
mTOR than nuclear raptor (Rosner and Hengstschla ¨ger, 2008).
They proposed distinct mechanisms for regulation of mTOR in
the cytoplasm and the nucleus, and such mechanisms may be
associated with clinical outcomes.
In this study, 31% of tumours showed no activation of p-mTOR,
despite of a high frequency of activated Akt. The rate of negative
p-mTOR in gastric cancer was similar to that in another study
(Lang et al, 2007). That study also showed that negative expression
of p-mTOR was observed in normal gastric mucosa, whereas its
positive expression was more frequent in advanced disease. In
tumours without p-mTOR expression, another signalling pathway,
such as Erk, may be activated. In pancreatic cancer, high
expression of phosphorylated Erk was associated with shorter
survival, whereas high expression of p-Akt was associated with
longer survival (Chadha et al, 2006). In breast cancer, p-mTOR
expression is predominantly detected in the cytoplasm and is
significantly associated with short RFS, but does not correlate with
any clinicopathological factors, including stage, histological grade,
and lymph node involvement (Zhou et al, 2004). Rajan et al found
that p-mTOR expression is unrelated to survival in pancreatic
cancer (Rajan et al, 2008). Boone et al reported that p-mTOR
expression is only associated with a lesser degree of tumour
differentiation (Boone et al, 2008). To our knowledge, however, no
earlier study has assessed nuclear p-mTOR expression. Our study
is the first to show that different localisation of mTOR expression
(i.e., cytoplasmic vs nuclear) was associated with different
outcomes in patients with cancer.
Phosphorylated Akt activates many downstream targets, includ-
ing mTOR, and is thought to play a role in tumour progression.
However, earlier studies of Akt expression in human cancers have
yielded conflicting results. In pancreatic cancer, one study showed a
correlation between higher p-Akt expression and shorter survival
(Yamamoto et al, 2004), whereas another study showed the opposite
(Chadha et al, 2006). Higher p-Akt expression was associated with
poor outcomes in breast cancer (Zhou et al, 2004), and with lymph
node metastasis or advanced disease stage in colorectal cancer (Itoh
et al, 2002). On the other hand, increased p-Akt expression
correlated with favourable outcomes in non-small-cell lung cancer
(Shah et al,2 0 0 5 ) .I ng a s t r i cc a n c e r ,N a met al reported that
tumours with p-Akt expression are associated with the absence of
lymph node metastasis and with longer survival in early-stage
disease (Nam et al, 2003). In our study, p-Akt expression was
frequently observed in both early and advanced gastric cancers and
was not related to clinicopathological factors or survival. These
discrepancies may be partly explained by differences in the type of
cancer studied, in the system used to classify p-Akt staining, or in
the expression of downstream targets of p-AKt, such as mTOR.
Several inhibitors of mTOR kinase have been evaluated in
various solid tumours, including renal, breast, pancreatic, and
endometrial cancer, and their anticancer efficacy has been shown
(Janus et al, 2005). The mTORC1 complex is sensitive to
rapamycin (Janus et al, 2005; Sarbassov et al, 2005). As mTORC1
complex is mainly found in the cytoplasm, tumours with
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Figure 2 Kaplan–Meier curves for the relapse-free survival of patients with expression of cytoplasmic p-mTOR (A), nuclear p-mTOR (B), cytoplasmic
p-Akt (D), and both nuclear p-Akt and cytoplasmic p-Akt (E). Kaplan–Meier curves for the four subgroups classified according to p-mTOR expression are
shown in (C).
Table 4 Prognostic factors in a multivariate Cox proportional-hazards
regression model
HR 95%Cl P-value
Age 0.98 0.94–10.2 0.35
Sex; female vs male 1.23 0.49–3.11 0.66
Pathological type; intestinal vs diffuse 0.88 0.38–2.05 0.77
Depth of invasion; T1 vs T2–4 6.62 1.32–33.4 0.022
Involved lymph nodes 3.09 1.04–9.21 0.043
Cytoplasmic p-mTOR 1.42 0.51–3.97 0.51
Nuclear p-mTOR 0.57 0.18–1.77 0.33
Cytoplasmic p-Akt 0.35 0.11–1.16 0.086
Nuclear p-Akt 0.16 0.80–3.99 0.16
Abbreviations: CI¼confidence interval; HR¼hazard ratio; p-Akt¼phosphorylated
Akt; p-mTOR¼phosphorylated mTOR.
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inhibitors than those with nuclear expression of mTOR. In addition,
Akt requires mTORC2 to achieve its full activation, suggesting that
inhibition of mTORC2 is essential for preventing the progression of
tumours with highly activated Akt/mTOR signalling.
In conclusion, cytoplasmic p-mTOR expression was associated
with tumour progression and poor survival in gastric cancer; the
opposite results were obtained for nuclear p-mTOR expression.
Localisation of p-mTOR might thus be critical to tumour
progression and outcomes in patients with gastric cancer.
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